”Where Do We Go From Here?” Targeted Therapies Lead to Challenging Choices in Breast Cancer

Newly approved targeted therapies for patients with advanced hormone
receptor (HR)-positive, HER2-negative breast cancer are changing care. “We
have an abundance of opportunities, but challenges with having to choose
the right opportunity at the right time,” says Robert A. Figlin, MD, the Steven
Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer
Center in Los Angeles. Dr. Figlin discusses how to navigate new options with
Manali Bhave, MD, a breast medical oncologist and assistant professor at the
Emory University School of Medicine in Atlanta. Dr. Bhave stresses that
disease progression in breast cancer can’t be addressed with a one-size-fits-
all option. “Where do we go from here? I think it is largely dependent on
clinical factors, patient comorbidities, and even biomarker status,” she
explains. Dr. Bhave and Dr. Figlin discuss recent developments in targeted
therapies and important challenges. “We’ve come a long way in treating
metastatic HR-positive, HER2-negative breast cancer as more of a chronic
disease,” she says.

Dr. Bhave reported consulting fees from Lilly, Novartis, and AstraZeneca.

Dr. Figlin reported various financial relationships.